These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19356612)

  • 1. A universal epitope-based influenza vaccine and its efficacy against H5N1.
    Adar Y; Singer Y; Levi R; Tzehoval E; Perk S; Banet-Noach C; Nagar S; Arnon R; Ben-Yedidia T
    Vaccine; 2009 Mar; 27(15):2099-107. PubMed ID: 19356612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope-based vaccine against influenza.
    Ben-Yedidia T; Arnon R
    Expert Rev Vaccines; 2007 Dec; 6(6):939-48. PubMed ID: 18034655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
    Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
    J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
    Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
    Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
    Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platycodin d improves the immunogenicity of newcastle disease virus-based recombinant avian influenza vaccine in mice.
    Xie Y; Sun HX; Li D
    Chem Biodivers; 2010 Mar; 7(3):677-89. PubMed ID: 20232336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.
    Ernst WA; Kim HJ; Tumpey TM; Jansen AD; Tai W; Cramer DV; Adler-Moore JP; Fujii G
    Vaccine; 2006 Jun; 24(24):5158-68. PubMed ID: 16713037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
    Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
    Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.